目的 探讨痫愈胶囊联合左乙拉西坦片治疗癫痫的临床疗效。方法 选取2017年1月—2017年12月在解放军第452医院就诊的癫痫患者92例为研究对象，按照随机数字表法分为对照组和治疗组，每组各46例。对照组口服左乙拉西坦片，初始剂量0.5 g/次，2次/d，治疗2周后，剂量变为1.0 g/次，2次/d。治疗组在对照组治疗的基础上口服痫愈胶囊，5粒/次，2次/d。两组患者均连续治疗6个月。观察两组的临床疗效，比较两组的认知功能、神经递质水平和癫痫发作频率。结果 治疗后，对照组和治疗组的总有效率分别为71.74%、82.61%，两组比较差异有统计学意义（P<0.05）。治疗后，两组注意、延迟回忆、定向、MoCA评分均明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组认知功能指标明显高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组神经胶质酸性蛋白（GFAP）、髓鞘碱性蛋白（MBP）水平均明显降低，脑源性神经营养因子（BDNF）水平明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组神经递质水平明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组发作频率明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组发作频率明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 痫愈胶囊联合左乙拉西坦片治疗癫痫具有较好的临床疗效，可改善认知功能，减少癫痫发作频率，调节神经递质水平，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Xianyu Capsules combined with Levetiracetam Tablets in treatment of epilepsy. Methods Patients (92 cases) with epilepsy in the 452 Hospital of People's Liberation Army from January 2017 to December 2017 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Levetiracetam Tablets, starting dosage 0.5 g/time, twice daily, after 2 weeks, dosage changed 1.0 g/time, twice daily. Patients in the treatment group were po administered with Xianyu Capsules on the basis of the control group, 5 grains/time, twice daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and cognitive function, the frequency of epileptic seizures, and neurotransmitter levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 71.74% and 82.61%, respectively, and there was difference between two groups (P < 0.05). After treatment, the scores of attention, delayed recollection, orientation, and MoCA in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the cognitive function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of GFAP and MBP in two groups were significantly decreased, but the levels of BDNF in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the neurotransmitter levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P <0.05).After treatment, the frequencies of epileptic seizures in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the frequency of epileptic seizures in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Xianyu Capsules combined with Levetiracetam Tablets has clinical curative effect in treatment of epilepsy, can improve cognitive function, reduce the frequency of epileptic seizures, regulate neurotransmitter, which has a certain clinical application value.